RANCHO CORDOVA, Calif., April 07, 2017 (GLOBE NEWSWIRE) -- Cesca Therapeutics Inc. (Nasdaq:KOOL), a market leader in automated cell processing and point-of-care, autologous cell-based therapies, today announced that Dr. Xiaochun (Chris) Xu, Chairman and Interim Chief Executive Officer, delivered the keynote speech, entitled, “Cell Therapy – The Next Wave of Future Medicine,” at the 2017 Shenzhen International Precision Medicine Summit, which took place yesterday and today (April 6-7) in Shenzhen, China. The summit was organized in honor of James D. Watson, Ph.D., who discovered the double helix structure of DNA in 1953 and later made a significant contribution to the Human Genome Project.
“As a leading developer of integrated cellular therapies and delivery systems, Cesca Therapeutics is uniquely positioned to advance the practice of regenerative medicine globally and we are therefore honored to have been asked to give the keynote speech at this important event,” commented Dr. Xu. “Earlier this year, we announced our intention to further expand into the China market, which has the world’s largest population and ranks among its fastest-growing economies. With this in mind, our long-term goal is to establish a leadership position in China through an expanded sales network and the creation of scientific and strategic collaborations that leverage our strong internal development capabilities in autologous cell-based therapies.”
About the International Precision Medicine Summit
The 2017 Shenzhen International Precision Medicine Summit is focused on new advances in precision medicine and brought together leaders in scientific research, the investment community and government officials, along with over 1,000 attendees from different countries. The conference covered hot topics in the field of immuno-oncology, cancer vaccines, cell therapeutics, genetic analysis and gene therapies.
About Cesca Therapeutics Inc.
Cesca is engaged in the research, development, and commercialization of cellular therapies and delivery systems for use in regenerative medicine. The Company is a leader in the development and manufacture of automated blood and bone marrow processing systems that enable the separation, processing and preservation of cell and tissue therapeutics. Cesca is an affiliate of the Boyalife Group (http://www.boyalifegroup.com), a China-based industrial-research alliance among top research institutes for stem cell and regenerative medicine.
The statements contained herein may include statements of future expectations and other forward-looking statements that are based on management’s current views and assumptions and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. A more complete description of risks that could cause actual events to differ from the outcomes predicted by Cesca Therapeutics' forward-looking statements is set forth under the caption "Risk Factors" in Cesca Therapeutics' annual report on Form 10-K and other reports it files with the Securities and Exchange Commission from time to time, and you should consider each of those factors when evaluating the forward-looking statements.
CONTACT: Investor Contact: Rx Communications Paula Schwartz 917-322-2216 firstname.lastname@example.org